The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...
A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain ...
The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...
Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...
Omnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare ...
Zacks Investment Research on MSN
Insulet broadens Omnipod 5 presence with commercial launch in Spain
Insulet Corporation PODD has commercially launched its Omnipod 5 Automated Insulin Delivery (AID) system and the Omnipod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results